First Preclinical Development Candidate for Nucleome Therapeutics
First-in-class monoclonal antibody agonist program for inflammation
01/19/2026
2 min read
False
Advertisement
Related Content
Small Molecules
Development & Clinical
Interviews
Musings from The Power List: Dajun Yang
September 15, 2026
4 min read
The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics
Small Molecules
Drug Discovery
Development & Clinical
Musings from The Power List: Ali Tavassoli
September 10, 2026
8 min read
Ali Tavassoli explains how cyclic peptides and new discovery tools are opening up once-inaccessible biology
Biopharma
Business & Trends
Technology & Manufacturing
The Manufacturing Questions Facing Chinese Biotech
September 9, 2026
5 min read
Lonza’s Wayne Wen discusses the growing maturity of China’s drug development and manufacturing ecosystem – and what companies need to compete internationally
Cell & Gene
Drug Discovery
Development & Clinical
Musings from The Power List: Miguel Forte
September 8, 2026
4 min read
Scientific progress alone isn't enough, says Miguel Forte, who argues that reimbursement and patient access will shape the next decade of cell and gene therapy